ArticleOncogene2002
Cre-loxP chromosome engineering of a targeted deletion in the mouse corresponding to the 3p21.3 region of homozygous loss in human tumours.
Article in Oncogene, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 38 citations in OpenAlex.
- A functional overlap between actively transcribed genes and chromatin insulator elements.The EMBO journal · 2026Article
- The α-globin super-enhancer acts in an orientation-dependent manner.Nature communications · 2025Article
- How CRISPR Is Revolutionizing the Generation of New Models for Cancer Research.Cold Spring Harbor perspectives in medicine · 2024Review
- Super-enhancers include classical enhancers and facilitators to fully activate gene expression.Cell · 2023Article
- Lineage tracing: technology tool for exploring the development, regeneration, and disease of the digestive system.Stem cell research & therapy · 2020Review
- Applications of Genome Editing Technology in Research on Chromosome Aneuploidy Disorders.Cells · 2020Review
- Identification of Novel Epigenetic Markers of Prostate Cancer by NotI-Microarray Analysis.Disease markers · 2015Article
- A new deletion refines the boundaries of the murine Prader-Willi syndrome imprinting center.Human molecular genetics · 2011Article
- Controlled somatic and germline copy number variation in the mouse model.Current genomics · 2010Article
- Chromosomal manipulation by site-specific recombinases and fluorescent protein-based vectors.PloS one · 2010Article
- Cancer gene discovery in mouse and man.Biochimica et biophysica acta · 2009Review
- Genetically modified mouse models in cancer studies.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2008Review
- CRE recombinase-based positive-negative selection systems for genetic manipulation in Trypanosoma brucei.Molecular and biochemical parasitology · 2008Article
- The Ras-association domain family (RASSF) members and their role in human tumourigenesis.Biochimica et biophysica acta · 2007Review
- Modeling chromosomes in mouse to explore the function of genes, genomic disorders, and chromosomal organization.PLoS genetics · 2006Review
- Loss of Atrx affects trophoblast development and the pattern of X-inactivation in extraembryonic tissues.PLoS genetics · 2006Article
- Mouse chromosome engineering for modeling human disease.Annual review of genomics and human genetics · 2006Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chromosomal deletions are a common feature of epithelial tumours and when further defined by homozygous deletions, are often the location of tumour suppressor genes. Deletions within the short arm of chromosome 3 occur very frequently in human carcinomas: a minimal region of loss at 3p21.3 (the Luca) region has been defined by overlapping homozygous deletions in lung and breast cancer cell lines. Using a rapid strategy for Cre-loxP chromosome engineering, a deletion of approximately 370 kb was created in the mouse germline corresponding to the deleted region at 3p21.3. The deletion when homozygous is embryonic lethal. Heterozygotes develop normally despite being haplo-insufficient for twelve genes including the candidate tumour suppressor gene Rassf1. Because damage to 3p21.3 often occurs very early in the sequence of genetic changes that lead to malignancy, particularly in lung and breast cancer, further genetic damage to these mice will provide the opportunity to model multi-step tumorigenesis of these tumours.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.